Black Swan Sale

50% Off Elite

Get our most powerful screeners, new charting tools, and the fastest ad-
free experience at our best price ever. This deal may never happen again.

ANNX

Annexon Inc

Nov 26 • 04:00PM ET

4.32

-0.12 -2.70 %

Healthcare • Biotechnology • USA • NASD

Nov 20, 10:03 AMWells Fargo's doubled price target to $27 triggered the 22% intraday surge.

Peers: VRTX RARE CRSP NTLA EDIT ALLO BLUE FOLD MYO SGMO

| Held by: IWM VTI IWN VXF IBB SCHA VTWO AVSC IWC PRFZ

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.41	Insider Own	14.29%	Shs Outstand	144.73M	Perf Week	6.40%
Market Cap	625.23M	Forward P/E	-	EPS next Y	-1.11	Insider Trans	12.76%	Shs Float	124.05M	Perf Month	25.22%
Enterprise Value	463.45M	PEG	-	EPS next Q	-0.32	Inst Own	66.29%	Short Float	7.04%	Perf Quarter	103.77%
Income	-208.88M	P/S	-	EPS this Y	-38.24%	Inst Trans	1.39%	Short Ratio	3.71	Perf Half Y	98.17%
Sales	0.00M	P/B	3.08	EPS next Y	20.72%	ROA	-68.11%	Short Interest	8.73M	Perf YTD	-15.79%
Book/sh	1.40	P/C	3.31	EPS next 5Y	5.95%	ROE	-83.99%	52W High	5.66 -23.67%	Perf Year	-15.95%
Cash/sh	1.30	P/FCF	-	EPS past 3/5Y	33.38% -0.09%	ROIC	-112.57%	52W Low	1.28 236.19%	Perf 3Y	-22.30%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	8.74% 9.52%	Perf 5Y	-82.67%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-35.62%	Oper. Margin	-	ATR (14)	0.34	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	4.42	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	70.15	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	4.42	EPS Q/Q	-47.97%	SMA20	27.96%	Beta	1.16	Target Price	14.00
Payout	-	Debt/Eq	0.17	Sales Q/Q	-	SMA50	34.79%	Rel Volume	1.27	Prev Close	4.44
Employees	100	LT Debt/Eq	0.15	Earnings	Nov 10 AMC	SMA200	71.85%	Avg Volume	2.35M	Price	4.32
IPO	Jul 24, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	-8.41% -	Trades		Volume	3,000,767	Change	-2.70%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-01-24	Upgrade	JP Morgan	Neutral → Overweight	$11
Dec-21-23	Upgrade	BofA Securities	Neutral → Buy	$4 → $6
Oct-30-23	Initiated	Wells Fargo	Overweight	$11
May-26-23	Downgrade	BofA Securities	Buy → Neutral	$8 → $3
May-25-23	Downgrade	JP Morgan	Overweight → Neutral	$19 → $9
Sep-16-22	Initiated	Jefferies	Buy	$12
Sep-09-22	Initiated	BTIG Research	Buy	$15
Nov-30-21	Initiated	H.C. Wainwright	Buy	$40
Sep-23-21	Initiated	Cantor Fitzgerald	Overweight	$40
Jan-26-21	Initiated	Needham	Buy	$37
Aug-18-20	Initiated	JP Morgan	Overweight	$33
Aug-18-20	Initiated	Cowen	Outperform
Aug-18-20	Initiated	BofA Securities	Buy	$33

Show Previous Ratings

Nov-14-25 04:01PM	Annexon Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $86.25 Million (GlobeNewswire) +11.44%
Nov-12-25 10:55PM	Annexon Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire) -5.63%
04:12PM	Annexon Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
Nov-10-25 04:05PM	Annexon Reports Third Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones (GlobeNewswire)
Sep-30-25 11:41AM	Nuveen Expands Portfolio With Annexon, Inc. (ANNX) Acquisition (Insider Monkey)
08:00AM	Loading…
Aug-27-25 08:00AM	Annexon Biosciences to Participate in Upcoming September Investor Conferences (GlobeNewswire)
Aug-18-25 04:05PM	Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.81%
Aug-14-25 04:05PM	Annexon Reports Second Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones (GlobeNewswire) -8.46%
Aug-11-25 07:29AM	Annexon announces EMA selection of vonaprument for PDC pilot participation (Pharmaceutical Business Review)
Aug-07-25 04:30PM	Annexon Selected by EMA to Participate in Product Development Coordinator Pilot for Vonaprument (ANX007) for Dry Age-Related Macular Degeneration with Geographic Atrophy (GlobeNewswire)
Jul-24-25 07:00AM	Annexon Announces Completion of Enrollment in Pivotal Phase 3 ARCHER II Trial of Vonaprument (formerly ANX007) for Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy (GlobeNewswire)
Jul-22-25 06:16AM	New Strong Sell Stocks for July 22nd (Zacks)
Jun-18-25 04:05PM	Annexon Bolsters Ophthalmology Expertise with Appointment of Retina Specialist Lloyd Clark, M.D., as Pivotal ANX007 Program Advances in Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy (GA) (GlobeNewswire)
May-29-25 04:05PM	Annexon Biosciences to Present at the Jefferies Global Healthcare Conference (GlobeNewswire) +7.39% -6.42%
May-19-25 04:05PM	Annexon Showcases Tanruprubart Data Demonstrating Improved Clinical Outcomes in Guillain-Barré Syndrome (GBS) at 2025 Peripheral Nerve Society (PNS) Annual Meeting (GlobeNewswire)
04:05PM	Loading…
04:05PM	Annexon Showcases Tanruprubart Data Demonstrating Improved Clinical Outcomes in Guillain-Barre Syndrome (GBS) at 2025 Peripheral Nerve Society (PNS) Annual Meeting (GlobeNewswire)
May-16-25 04:05PM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +11.05%
May-12-25 08:00AM	Annexon Reports First Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones (GlobeNewswire) +10.62%
May-09-25 05:00PM	Annexon Announces Presentations on the Clinical Advancement of Tanruprubart as the First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) at the 2025 PNS Meeting (GlobeNewswire) -5.88%
05:00PM	Annexon Announces Presentations on the Clinical Advancement of Tanruprubart as the First Potential Targeted Therapy for Guillain-Barre Syndrome (GBS) at the 2025 PNS Meeting (GlobeNewswire)
May-07-25 08:00AM	Annexon to Present on the Neuroprotective Effects of ANX007 at the 2025 ARVO Annual Meeting and the Retina World Congress (GlobeNewswire)
Apr-16-25 04:05PM	Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -7.14%
Apr-15-25 07:12AM	Annexon: With IGOS Study Completion, Pre-BLA Meeting In 1st Half 2025 On Deck (Seeking Alpha)
Apr-10-25 09:24AM	Why Annexon Inc. (ANNX) Went Down On Thursday? (Insider Monkey)
Apr-09-25 03:20PM	Annexon's Investigational Drug Shows Rapid Recovery And Durable Benefit In Rare Neurological Disorder (Benzinga) -7.79%
Apr-08-25 04:05PM	Annexon Highlights Pivotal Data on First Potential Targeted Therapy for Guillain-Barre Syndrome (GBS) and Showcases New GBS Education Campaign at American Academy of Neurology (AAN) 2025 Annual Meeting (GlobeNewswire) -5.52%
04:05PM	Annexon Highlights Pivotal Data on First Potential Targeted Therapy for Guillain-Barr Syndrome (GBS) and Showcases New GBS Education Campaign at American Academy of Neurology (AAN) 2025 Annual Meeting (GlobeNewswire)
Apr-03-25 06:18PM	Annexon Highlights Leadership in Advancing Clinical Research and Education for Guillain-Barre Syndrome (GBS) at American Academy of Neurology (AAN) 2025 Annual Meeting (GlobeNewswire) -6.63% -7.65%
06:18PM	Annexon Highlights Leadership in Advancing Clinical Research and Education for Guillain-Barr Syndrome (GBS) at American Academy of Neurology (AAN) 2025 Annual Meeting (GlobeNewswire)
Mar-17-25 04:05PM	Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.77% -9.09%
06:05AM	Loading…
Mar-16-25 06:05AM	Wells Fargo Predicts Up to ~440% Rally for These 2 Strong Buy Stocks (TipRanks)
Mar-03-25 08:00AM	Annexon Reports Fourth Quarter and Year-End 2024 Financial Results, Portfolio Progress and Key Anticipated Milestones (GlobeNewswire) -9.47%
Feb-26-25 04:05PM	Annexon Biosciences to Present at the TD Cowen 45th Annual Health Care Conference (GlobeNewswire)
Feb-18-25 08:00AM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -12.05%
Feb-13-25 08:30AM	Annexon Announces Presentations Highlighting ANX007 Functional and Structural Differentiation in Geographic Atrophy at the Macula Society 48th Annual Meeting (GlobeNewswire)
Jan-13-25 08:00AM	Annexon Provides 2025 Outlook with Strong Momentum Accelerating into Breakthrough Year (GlobeNewswire)
Jan-10-25 08:00AM	Annexon Expands Board of Directors with Appointment of Commercial Executive William BJ Jones (GlobeNewswire)
Jan-07-25 08:00AM	Annexon Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-16-24 04:05PM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +13.96%
07:30AM	Annexon Announces Positive Topline Results from Real-World Evidence Study Comparing ANX005 Treatment to Intravenous Immunoglobulin (IVIg) or Plasma Exchange (PE) in a Matched Patient Cohort for the Treatment of Guillain-Barr Syndrome (GBS) (GlobeNewswire)
Dec-05-24 08:00AM	Annexon to Present Phase 2 ARCHER Data on Protection of Vision and Photoreceptors with ANX007 in Geographic Atrophy at the Floretina-ICOOR 2024 Meeting (GlobeNewswire)
Nov-19-24 03:00AM	The Dodgers World Series run brought attention to a rare disease. Annexon is stepping up to the plate. (Pharma Voice)
Nov-15-24 04:59PM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -10.78%
Nov-14-24 08:00AM	Annexon Reports Third Quarter 2024 Portfolio and Financial Results, and Key Anticipated Milestones (GlobeNewswire)
Nov-13-24 04:05PM	Annexon Biosciences to Present at the Jefferies London Healthcare Conference (GlobeNewswire)
Oct-21-24 08:00PM	Annexon Presents Phase 2 Vision Preservation Data with ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting (GlobeNewswire)
Oct-16-24 08:00AM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-15-24 08:00AM	Annexon to Present New Phase 2 ARCHER Data for ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting (GlobeNewswire)
Sep-16-24 08:00AM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-09-24 08:00AM	Annexon to Present Phase 2 ARCHER Data on Protection of Vision and Photoreceptors with ANX007 in GA at the Retina Society 57th Annual Meeting and 24th Euretina Congress (GlobeNewswire) +8.17%
Sep-03-24 08:00AM	Annexon Expands Senior Leadership in Commercial, Medical Affairs and Health Economics to Advance Global Late-Stage Neuroinflammatory-Targeted Portfolio (GlobeNewswire) -5.09%
Aug-29-24 08:00AM	Annexon Biosciences to Participate in Upcoming September Investor Conferences (GlobeNewswire)
Aug-16-24 04:05PM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-12-24 08:00AM	Annexon Reports Second Quarter 2024 Portfolio and Financial Results, and Key Anticipated Milestones (GlobeNewswire)
Aug-05-24 08:00AM	Annexon Provides Update on ARCHER II Global Registrational Program in Geographic Atrophy (GlobeNewswire) -9.38%
Jul-16-24 04:05PM	Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.02%
Jul-11-24 06:09PM	Annexon to Present Additional Phase 2 Data Showing Preservation of Visual Function and Structure by ANX007 in Geographic Atrophy at the 42nd ASRS Annual Scientific Meeting (GlobeNewswire) +8.53% +11.15%
Jun-29-24 08:48PM	Are Analysts Bullish on Annexon, Inc. (ANNX) Right Now? (Insider Monkey)
Jun-28-24 09:40AM	Are Medical Stocks Lagging Annexon (ANNX) This Year? (Zacks)
Jun-27-24 09:55AM	Here's Why Annexon (ANNX) Is a Great 'Buy the Bottom' Stock Now (Zacks)
Jun-25-24 05:00PM	Annexon Presented Additional Positive Phase 3 Results for ANX005 C1q-Targeted Immunotherapy in Guillain-Barre Syndrome at the 2024 PNS Annual Meeting (GlobeNewswire)
05:00PM	Annexon Presented Additional Positive Phase 3 Results for ANX005 C1q-Targeted Immunotherapy in Guillain-Barr Syndrome at the 2024 PNS Annual Meeting (GlobeNewswire)
Jun-24-24 06:35AM	7 Top Stocks Under $10: June 2024 Edition (InvestorPlace)
Jun-18-24 08:00AM	Annexon To Present Pivotal Phase 3 Data On Early And Durable Benefits With First-In-Class C1q Blocking Antibody ANX005 In Guillain-Barr Syndrome At 2024 PNS Annual Meeting (GlobeNewswire) -5.41%
Jun-17-24 04:05PM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-07-24 09:40AM	Is Annexon (ANNX) Stock Outpacing Its Medical Peers This Year? (Zacks)
Jun-05-24 11:04PM	Annexon Announces Pricing of $125 Million Underwritten Public Offering (GlobeNewswire) +13.36% -13.25%
10:57AM	Annexon (ANNX) Up as Phase III Neuro Disorder Study Meets Goals (Zacks)
09:55AM	Wall Street Analysts Think Annexon (ANNX) Could Surge 133.72%: Read This Before Placing a Bet (Zacks)
04:45AM	Annexons ANX005 offers improvement in Phase III GBS trial (Clinical Trials Arena)
Jun-04-24 05:06PM	Annexon Announces Proposed Public Offering of Common Stock (GlobeNewswire) +30.79%
12:06PM	Mid-Cap Firm Annexon's Nerve Disorder Candidate Shows Promise In Pivotal Late-Stage Study (Benzinga)
08:46AM	Annexon shares leap as Guillain-Barr drug reduces disability in phase 3 (FierceBiotech.com)
07:28AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace)
07:00AM	Annexon Announces Positive Topline Results from Pivotal Phase 3 Trial for First-in-Class C1q Blocking Antibody ANX005 in Guillain-Barre Syndrome (GlobeNewswire)
07:00AM	Annexon Announces Positive Topline Results from Pivotal Phase 3 Trial for First-in-Class C1q Blocking Antibody ANX005 in Guillain-Barr Syndrome (GlobeNewswire)
Jun-03-24 04:30PM	Annexon Biosciences to Host Conference Call and Webcast to Discuss GBS Phase 3 Data (GlobeNewswire) -5.18%
May-20-24 09:35AM	Annexon (ANNX) Loses -5.04% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks) +8.08%
May-16-24 04:05PM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-13-24 02:53PM	ANNX Stock Earnings: Annexon Beats EPS for Q1 2024 (InvestorPlace)
08:00AM	Annexon Reports First Quarter 2024 Financial Results and Key Anticipated Milestones (GlobeNewswire)
May-09-24 08:00AM	Annexon Biosciences to Present at the Bank of America Health Care Conference (GlobeNewswire)
May-07-24 12:30PM	Annexon Presents New Neuroprotection Data Showing ANX007 Protects Vision and Vision-Associated Structures in Geographic Atrophy at ARVO 2024 Annual Meeting (GlobeNewswire)
May-01-24 10:15AM	Annexon (ANNX) to Report Q1 Earnings: What's in the Cards? (Zacks)
08:00AM	Annexon to Present Data Reinforcing the Neuroprotective Effects of ANX007 and C1q Inhibition in Geographic Atrophy at the ARVO 2024 Annual Meeting (GlobeNewswire)
Apr-25-24 09:35AM	Down -43.02% in 4 Weeks, Here's Why You Should You Buy the Dip in Annexon (ANNX) (Zacks)
Apr-17-24 09:40AM	Are Medical Stocks Lagging Annexon (ANNX) This Year? (Zacks) -10.36%
Apr-16-24 04:05PM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -10.89%
09:00AM	Turnstone Biologics Appoints William Waddill to its Board of Directors (GlobeNewswire)
Apr-14-24 12:52PM	10 Buy-Rated Stocks with Latest Insider Purchases (Insider Monkey)
Apr-10-24 06:15PM	Annexon, Inc. (ANNX) Falls More Steeply Than Broader Market: What Investors Need to Know (Zacks)
Apr-03-24 08:00AM	Annexon Biosciences to Present at the 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Apr-01-24 12:00PM	What Makes Annexon (ANNX) a New Buy Stock (Zacks) -7.53%
09:55AM	Wall Street Analysts Believe Annexon (ANNX) Could Rally 101.12%: Here's is How to Trade (Zacks)
Mar-28-24 05:31AM	Annexon Inc (ANNX) Reports Year-End Financials, Aligns with Analyst Projections (GuruFocus.com) -8.19%
Mar-26-24 08:53PM	ANNX Stock Earnings: Annexon Beats EPS for Q4 2023 (InvestorPlace) +13.52%
04:05PM	Annexon Reports Fourth Quarter and Year-End 2023 Financial Results and Key Anticipated Milestones (GlobeNewswire)
Mar-18-24 04:05PM	Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.98%
Mar-14-24 08:40AM	Why Annexon (ANNX) Might Surprise This Earnings Season (Zacks)
Mar-12-24 02:51PM	J.P. Morgan Predicts up to 140% Rally for These 2 Strong Buy Stocks (TipRanks)

Annexon, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, eye and brain. It offers drugs that control or target huntington's and alzheimer's disease, multiple sclerosis, glaucoma, parkinson's disease, and spinal muscular atrophy. The company was founded by Ben Barres and Arnon Rosenthal on March 3, 2011 and is headquartered in Brisbane, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Satter Muneer A	Director	Nov 21 '25	Buy	4.28	422,613	1,808,784	9,728,637	Nov 21 09:52 PM
Satter Muneer A	Director	Nov 20 '25	Buy	4.48	400,000	1,792,000	9,306,024	Nov 21 09:52 PM
Satter Muneer A	Director	Nov 19 '25	Buy	3.94	500,000	1,970,000	8,906,024	Nov 19 09:00 PM
Satter Muneer A	Director	Nov 18 '25	Buy	3.18	500,000	1,590,000	8,406,024	Nov 19 09:00 PM
Satter Muneer A	Director	Nov 17 '25	Buy	2.99	500,000	1,495,000	7,906,024	Nov 19 09:00 PM
Carson William H.	Director	Oct 30 '25	Buy	3.17	4,115	13,045	46,175	Oct 31 04:15 PM
Carson William H.	Director	Sep 30 '25	Buy	3.05	4,115	12,551	42,060	Oct 02 04:17 PM
Carson William H.	Director	Sep 02 '25	Buy	2.09	4,115	8,600	37,945	Sep 04 04:30 PM
Carson William H.	Director	Jul 30 '25	Buy	2.43	4,115	9,999	33,830	Aug 01 04:30 PM
Yednock Ted	EVP & CHIEF INNOVATION OFFICER	Jul 14 '25	Sale	2.58	1,116	2,879	105,084	Jul 16 04:20 PM
Lew Jennifer	EVP & CHIEF FINANCIAL OFFICER	Jul 14 '25	Sale	2.58	1,117	2,882	121,616	Jul 16 04:20 PM
Overdorf Michael	EVP & CHIEF BUSINESS OFFICER	Jul 14 '25	Sale	2.61	853	2,226	130,689	Jul 16 04:20 PM
Yednock Ted	Officer	Jul 14 '25	Proposed Sale	2.58	1,116	2,881		Jul 14 03:51 PM
Overdorf Michael	Officer	Jul 14 '25	Proposed Sale	2.61	853	2,226		Jul 14 03:26 PM
Lew Jennifer	Officer	Jul 14 '25	Proposed Sale	2.58	1,117	2,881		Jul 14 03:17 PM
Carson William H.	Director	Jun 30 '25	Buy	2.46	4,115	10,123	29,715	Jul 01 04:55 PM
Dananberg Jamie	CHIEF MEDICAL OFFICER	Feb 18 '25	Sale	2.96	5,521	16,342	33,479	Feb 20 04:54 PM
ARTIS DEAN RICHARD	EVP & CHIEF SCIENTIFIC OFFICER	Feb 18 '25	Sale	2.97	5,515	16,380	83,814	Feb 20 04:52 PM
Yednock Ted	EVP & CHIEF INNOVATION OFFICER	Feb 18 '25	Sale	2.91	8,345	24,284	61,237	Feb 20 04:51 PM
Overdorf Michael	EVP & CHIEF BUSINESS OFFICER	Feb 18 '25	Sale	2.95	6,618	19,523	86,579	Feb 20 04:49 PM
Lew Jennifer	EVP & CHIEF FINANCIAL OFFICER	Feb 18 '25	Sale	2.92	6,912	20,183	77,770	Feb 20 04:48 PM
Love Douglas	PRESIDENT AND CEO	Feb 13 '25	Sale	2.95	5,021	14,812	351,554	Feb 18 04:30 PM
Lew Jennifer	EVP & CHIEF FINANCIAL OFFICER	Feb 13 '25	Sale	2.98	1,786	5,322	84,682	Feb 18 04:30 PM
Overdorf Michael	EVP & CHIEF BUSINESS OFFICER	Feb 13 '25	Sale	2.99	1,425	4,261	93,197	Feb 18 04:30 PM
Yednock Ted	EVP & CHIEF INNOVATION OFFICER	Feb 13 '25	Sale	2.99	1,783	5,331	69,582	Feb 18 04:30 PM
Yednock Ted	Officer	Feb 18 '25	Proposed Sale	2.91	8,345	24,321		Feb 18 03:21 PM
Lew Jennifer	Officer	Feb 18 '25	Proposed Sale	2.92	8,338	24,319		Feb 18 03:15 PM
ARTIS DEAN RICHARD	Officer	Feb 18 '25	Proposed Sale	2.97	5,515	16,359		Feb 18 03:15 PM
Dananberg Jamie	Officer	Feb 18 '25	Proposed Sale	2.96	5,521	16,359		Feb 18 03:13 PM
Overdorf Michael	Officer	Feb 18 '25	Proposed Sale	2.95	6,618	19,514		Feb 18 03:11 PM
Yednock Ted	Officer	Feb 13 '25	Proposed Sale	2.98	1,783	5,316		Feb 13 03:18 PM
Love Douglas	Officer	Feb 13 '25	Proposed Sale	2.95	5,021	14,799		Feb 13 03:13 PM
Lew Jennifer	Officer	Feb 13 '25	Proposed Sale	2.98	1,786	5,314		Feb 13 03:12 PM
Overdorf Michael	Officer	Feb 13 '25	Proposed Sale	2.99	1,425	4,265		Feb 13 03:06 PM
Love Douglas	PRESIDENT AND CEO	Jan 06 '25	Option Exercise	1.41	37,994	53,556	356,575	Jan 08 05:58 PM
Carson William H.	Director	Dec 02 '24	Buy	5.33	3,200	17,056	25,600	Dec 04 06:12 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Black Swan Sale

50% Off Elite

ANNX

Annexon Inc

Upgrade your FINVIZ experience